Reata Pharmaceuticals has updated the timing of coming data announcements for two ongoing mid-stage trials for rare renal diseases. Source: BioSpace

PharmaCyte Biotech recently discussed its options and plans for a Phase IIb clinical trial of its Cell-in-a-Box technology in pancreatic cancer. Source: BioSpace

Galera Therapeutics has initiated its Phase I/II clinical trial of GC4419 in locally advanced pancreatic cancer (LAPC). Source: BioSpace

After a huge dry spell in M&A, 2018 is shaping up to be a great year for deal making. Source: BioSpace

The U.S. Food and Drug Administration stunned the company with a Refusal to File letter regarding its New Drug Application (NDA) for multiple sclerosis treatment ozanimod. Source: BioSpace

Gene-editing company Inscripta, formerly known as Muse Biotechnologies, will be able to expand its research capabilities and increase hiring after the company closed a Series C funding round of $55.5…

David Lucchino, chief executive officer of Frequency Therapeutics, is expected to be named the next chairman of MassBio next month. Source: BioSpace

Aldeyra Therapeutics has signed a collaboration research deal with Janssen Research & Development, a Johnson & Johnson company. Source: BioSpace

French company DBV Technologies is seeing some positive results from its milk allergy treatment. Source: BioSpace

Cambridge, Massachusetts-based Generation Bio closed on a $100 million Series B financing today. Source: BioSpace